Disc Medicine IRON Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -35.8%-12.5pp | -35.9%-8.1pp | -34.8%-9.8pp | -26.4%-5.2pp | -23.3%+4.9pp | |
| Return on assets | -33.1%-11.2pp | -32.6%-7.3pp | -32.2%-8.4pp | -24.7%-4.4pp | -21.9%+5.0pp | |
| Return on invested capital | -44.3%— | -49.1%— | -55%— | -46.4%— | —— | |
| Liquidity | ||||||
| Current ratio | 24×-13.6× | 21.9×+0.8× | 23.5×+4.1× | 32.1×+7.1× | 37.7×+14.0× | |
| Quick ratio | 24×-13.6× | 21.9×+0.8× | 23.5×+4.1× | 32.1×+7.1× | 37.7×+14.0× | |
| Cash ratio | 2.9×-3.7× | 2.5×-5.8× | 5.3×-2.3× | 6.2×-7.6× | 6.5×-16.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0.1×+0.1× | 0.1×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -74.7×+19.3× | -65.4×+161× | -61.8×— | -70.9×— | -94.1×— | |
| Per Share | ||||||
| Book value per share | $17.89-9.7% | $20.96+30.4% | $16.30+4.3% | $17.54-8.0% | $19.82+45.4% | |
| Valuation | ||||||
| Market capitalization | $2.44B+42.2% | $3B+58.9% | $2.3B+82.3% | $1.9B+70.4% | $1.72B+11.1% | |
| Enterprise value | $2.38B+46.7% | $2.94B+70.4% | $2.19B+105% | $1.81B+115% | $1.62B+34.9% | |
| Price / book | 3.5×+0.9× | 4.1×-0.2× | 4×+1.3× | 3.1×+0.8× | 2.6×-2.0× | |
| Free cash flow yield | -8.3%-2.2pp | -6%-1.0pp | -7.2%-0.5pp | -7.1%-0.5pp | -6%-1.4pp | |
| Earnings yield | -9.9%-3.1pp | -7.1%-1.3pp | -7.9%+0.3pp | -7.6%+0.5pp | -6.8%-1.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Disc Medicine's ratios come from?
- Every ratio is computed from Disc Medicine's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.